{"id":78066,"date":"2018-07-21T15:36:41","date_gmt":"2018-07-21T13:36:41","guid":{"rendered":"https:\/\/www.formycon.com\/company\/history\/"},"modified":"2025-01-10T09:52:33","modified_gmt":"2025-01-10T08:52:33","slug":"history","status":"publish","type":"page","link":"https:\/\/www.formycon.com\/en\/company\/history\/","title":{"rendered":"History"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; shift_y_fixed=&#8221;yes&#8221; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243;][vc_row_inner row_inner_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; equal_height=&#8221;yes&#8221; gutter_size=&#8221;0&#8243; shift_y=&#8221;0&#8243;][vc_column_inner column_width_use_pixel=&#8221;yes&#8221; position_vertical=&#8221;middle&#8221; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;2&#8243; align_mobile=&#8221;align_center_mobile&#8221; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; column_width_pixel=&#8221;800&#8243;][vc_custom_heading text_color=&#8221;color-155072&#8243; heading_semantic=&#8221;h1&#8243; text_size=&#8221;h5&#8243; text_weight=&#8221;700&#8243; text_transform=&#8221;uppercase&#8221; text_space=&#8221;fontspace-210350&#8243; separator=&#8221;yes&#8221; separator_color=&#8221;yes&#8221;]<\/p>\n<p style=\"text-align: center;\">History<\/p>\n<p>[\/vc_custom_heading][vc_custom_heading text_color=&#8221;color-186842&#8243; heading_semantic=&#8221;p&#8221; text_weight=&#8221;700&#8243;]A scientific legacy spanning two decades[\/vc_custom_heading][vc_custom_heading heading_semantic=&#8221;p&#8221; text_size=&#8221;h3&#8243; text_weight=&#8221;300&#8243; text_height=&#8221;fontheight-357766&#8243;]With the company\u2019s founding roots in Scil Group, an offshoot of Boehringer Mannheim, Formycon\u2019s organization and biopharmaceutical development expertise date back much farther than its name.[\/vc_custom_heading][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;5&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;0&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_fixed=&#8221;yes&#8221; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243;][vc_tabs history=&#8221;yes&#8221;][vc_tab gutter_size=&#8221;2&#8243; column_padding=&#8221;2&#8243; title=&#8221;2022&#8243; tab_id=&#8221;1676283326016-11-9&#8243; slug=&#8221;2022&#8243;][vc_row_inner][vc_column_inner column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-674378&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; css_animation=&#8221;bottom-t-top&#8221; width=&#8221;1\/1&#8243; column_width_pixel=&#8221;864&#8243;][vc_column_text text_lead=&#8221;yes&#8221; uncode_shortcode_id=&#8221;160109&#8243;]<\/p>\n<ul>\n<li>SARS-CoV-2 drug FYB207 shows<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/fyb207-shows-longer-half-life-and-improved-efficacy\/\" target=\"_blank\" rel=\"noopener\"> longer half-life and improved efficacy<\/a><\/li>\n<li>Formycon publishes<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-publishes-details-of-a-previously-undisclosed-pipeline-project-fyb206-is-a-biosimilar-candidate-for-keytruda-pembrolizumab\/\" target=\"_blank\" rel=\"noopener\"> details of pipeline project FYB206<\/a><\/li>\n<li><a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/european-commission-approves-fyb201-ranivisio1-ranivisio-ranibizumab-a-biosimilar-to-lucentis2\/\" target=\"_blank\" rel=\"noopener\">European Commission approves FYB201<\/a><\/li>\n<li>Formycon&#8217;s Biosimilar Ustekinumab Candidate <a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycons-biosimilar-ustekinumab-candidate-fyb202-shows-comparable-efficacy-to-reference-product-stelara-in-phase-iii-study\/\" target=\"_blank\" rel=\"noopener\">FYB202 shows comparable efficacy to reference product Stelara\u00ae in Phase III Study<\/a><\/li>\n<li><a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/u-s-food-and-drug-administration-fda-approved-fyb201-cimerlitm1-ranibizumab-eqrn-the-first-and-only-biosimilar-interchangeable-with-lucentis2\/\" target=\"_blank\" rel=\"noopener\">FDA approved FYB201\/CIMERLI\u2122<\/a> (ranibizumab-eqrn), the first and only biosimilar interchangeable with Lucentis\u00ae<\/li>\n<li>Formycon publishes <a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-publishes-update-on-development-projects\/\" target=\"_blank\" rel=\"noopener\">update on Development Projects<\/a><\/li>\n<li>Formycon Reports First Quarter 2022 Financial Results and Announces<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-reports-first-quarter-2022-financial-results-and-announces-development-start-of-two-new-biosimilar-candidates-fyb208-and-fyb209\/\" target=\"_blank\" rel=\"noopener\"> Development Start of two New Biosimilar Candidates FYB208 and FYB209<\/a><\/li>\n<li>Formycon appoints <a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-appoints-dr-stefan-glombitza-as-ceo-and-sets-the-course-for-the-future-by-appointing-the-two-experienced-pharmaceutical-managers-nicola-mikulcik-and-dr-andreas-seidl-to-the-executive-board\/\" target=\"_blank\" rel=\"noopener\">Dr. Stefan Glombitza as CEO and appoints Nicola Mikulcik and Dr. Andreas Seidl<\/a> to the Executive Board<\/li>\n<li>United Kingdom Medicines and Healthcare Products Regulatory Agency<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/united-kingdom-medicines-and-healthcare-products-regulatory-agency-mhra-grants-marketing-authorization-for-fyb201-formycons-biosimilar-for-lucentis1-to-be-commercialized-by-teva-as-ongavia\/\" target=\"_blank\" rel=\"noopener\"> MHRA grants Marketing Authorization for FYB201<\/a>, Formycon&#8217;s Biosimilar for Lucentis\u00ae\u00b9<\/li>\n<li><a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-ag-and-athos-kg-announce-closing-of-transaction-to-acquire-biosimilar-assets-fyb201-and-fyb202-as-well-as-bioeq-gmbh\/\" target=\"_blank\" rel=\"noopener\">Formycon AG and ATHOS KG announce closing of transaction<\/a> to acquire biosimilar assets FYB201 and FYB202 as well as Bioeq GmbH<\/li>\n<li><a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-and-athos-kg-merge-development-activities-through-the-acquisition-of-biosimilar-assets-in-a-long-term-strategic-partnership\/\" target=\"_blank\" rel=\"noopener\">Formycon and ATHOS KG merge development activities<\/a> in a long-term strategic partnership<\/li>\n<\/ul>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_tab][vc_tab title=&#8221;2021&#8243; tab_id=&#8221;1642499690842-10-8&#8243; slug=&#8221;2021&#8243;][vc_row_inner][vc_column_inner column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-674378&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; css_animation=&#8221;bottom-t-top&#8221; width=&#8221;1\/1&#8243; column_width_pixel=&#8221;864&#8243;][vc_column_text text_lead=&#8221;yes&#8221;]<\/p>\n<ul>\n<li>MS Pharma becomes <a href=\"https:\/\/www.formycon.com\/en\/press-release\/ms-pharma-becomes-partner-for-the-commercialization-of-fyb201-formycons-biosimilar-candidate-to-lucentisr1-ranibizumab-in-the-mena-region\/\">exclusive partner<\/a> for the commercialization of FYB201 in the MENA region<\/li>\n<li>Formycon and Scientists from TUM publish<a href=\"https:\/\/www.formycon.com\/en\/press-release\/formycon-and-scientists-from-tum-publish-new-data-on-broadly-effective-sars-cov-2-antiviral-drug-fyb207\/\"> new Data on FYB207<\/a><\/li>\n<li>Formycon and SCG Cell Therapy announce <a href=\"https:\/\/www.formycon.com\/en\/press-release\/formycon-and-scg-cell-therapy-announce-collaboration-and-license-agreement-for-formycons-covid-19-drug-fyb207\/\">Collaboration and License Agreement<\/a> for FYB207<\/li>\n<li>Formycon and Bioeq announce <a href=\"https:\/\/www.formycon.com\/en\/press-release\/formycon-and-bioeq-announce-file-acceptance-for-fyb201-a-biosimilar-candidate-to-lucentis-ranibizumab-by-the-u-s-food-and-drug-administration-fda\/\">File Acceptance<\/a> for FYB201 by the FDA<\/li>\n<li>Formycon\u2019s COVID-19 drug FYB207 wins <a href=\"https:\/\/www.formycon.com\/en\/press-release\/formycons-covid-19-drug-fyb207-wins-prestigious-pharma-trend-image-innovation-award-2021\/\">Pharma Trend Image &amp; Innovation Award<\/a><\/li>\n<li>Formycon and Bioeq announce<a href=\"https:\/\/www.formycon.com\/en\/press-release\/formycon-and-bioeq-announce-submission-of-the-biologics-license-application-bla-for-fyb201-a-biosimilar-candidate-to-lucentisr1-ranibizumab-to-the-u-s-food-and-drug-administration-fda\/\"> submission of the biologics license application<\/a> to the FDA<\/li>\n<li>Formycon receives Euro 12.7 million <a href=\"https:\/\/www.formycon.com\/en\/press-release\/formycon-receives-euro-12-7-million-grant-for-further-development-of-covid-19-drug-fyb207-as-part-of-the-bavarian-therapy-strategy-to-combat-the-covid-19-pandemic\/\">grant<\/a> for further development of FYB207<\/li>\n<li>Formycon and Bioeq announce <a href=\"https:\/\/www.formycon.com\/en\/press-release\/formycon-and-bioeq-announce-submission-of-the-marketing-authorization-application-for-fyb201-a-biosimilar-candidate-to-lucentisr1-ranibizumab-to-the-european-medicines-agency-ema\/\">submission of the marketing authorization application<\/a> for FYB201 to the EMA<\/li>\n<li>Teva Pharmaceutical becomes <a href=\"https:\/\/www.formycon.com\/en\/press-release\/teva-pharmaceutical-industries-ltd-becomes-strategic-partner-for-the-commercialization-of-fyb201-formycons-biosimilar-candidate-to-lucentisr1-ranibizumab-in-europe-canada-israel-and-new-zeala\/\">strategic partner<\/a> for the commercialization of FYB201 in Europe, Canada, Israel and New Zealand<\/li>\n<li>Formycon\u2019s COVID-19 Drug<a href=\"https:\/\/www.formycon.com\/en\/press-release\/formycons-covid-19-drug-fyb207-even-more-efficient-against-sars-cov-2-mutant-b-1-1-7\/\"> FYB207 even more efficient against SARS-CoV-2 Mutant B.1.1.7<\/a><\/li>\n<li>Formycon receives positive <a href=\"https:\/\/www.formycon.com\/en\/press-release\/formycon-receives-positive-scientific-advice-from-paul-ehrlich-institute-for-the-covid-19-drug-fyb207-and-assures-gmp-manufacturing-capacities\/\">Scientific Advice<\/a> from Paul-Ehrlich-Institute for the COVID-19 Drug FYB207<\/li>\n<\/ul>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_tab][vc_tab title=&#8221;2020&#8243; tab_id=&#8221;1612444436597-9-0&#8243; slug=&#8221;2020&#8243;][vc_row_inner][vc_column_inner column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-674378&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; css_animation=&#8221;bottom-t-top&#8221; width=&#8221;1\/1&#8243; column_width_pixel=&#8221;864&#8243;][vc_column_text text_lead=&#8221;yes&#8221;]<\/p>\n<ul>\n<li>Innovative <a href=\"https:\/\/www.formycon.com\/en\/press-release\/innovative-sars-cov-2-blocker-from-formycon-completely-prevents-infection-of-cells\/\">SARS-CoV-2-Blocker<\/a> from Formycon completely prevents infection of cells<\/li>\n<li>Chief Operating Officer <a href=\"https:\/\/www.formycon.com\/en\/press-release\/chief-operating-officer-dr-stefan-glombitza-appointed-to-formycon-ags-management-board-for-another-four-years\/\">Dr. Stefan Glombitza<\/a> appointed to Formycon&#8217;s Management Board for another four years<\/li>\n<li>Formycon and Bioeq announce launch of <a href=\"https:\/\/www.formycon.com\/en\/press-release\/formycon-and-bioeq-announce-launch-of-phase-iii-study-of-fyb202-a-biosimilar-candidate-for-stelarar-ustekinumab\/\">phase III study<\/a> with ustekinumab biosimilar candidate FYB202<\/li>\n<li>Formycon informs about the <a href=\"https:\/\/www.formycon.com\/en\/press-release\/formycon-informs-about-the-modified-bla-submission-strategy-for-its-lucentisr-biosimilar-candidate-fyb201\/\">modified BLA-submission<\/a> strategy for its Lucentis\u00ae Biosimilar-Candidate FYB201<\/li>\n<li>Formycon receives <a href=\"https:\/\/www.formycon.com\/en\/press-release\/formycon-receives-funding-for-covid-19-drug-research-from-the-bavarian-research-foundation\/\">funding<\/a> for COVID-19 drug research from the Bavarian Research Foundation<\/li>\n<li>Formycon places <a href=\"https:\/\/www.formycon.com\/en\/press-release\/strategic-investor-active-ownership-group-subscribes-for-cash-capital-increase-of-eur-25-75-million\/\">cash capital increase<\/a> of 25.75 Million Euros with strategic investor<\/li>\n<li>Formycon and Bioeq enroll first patient in <a href=\"https:\/\/www.formycon.com\/en\/press-release\/formycon-and-bioeq-enroll-first-patient-in-phase-iii-study-with-aflibercept-biosimilar-fyb203\/\">phase III study<\/a> with aflibercept biosimilar (FYB203)<\/li>\n<li>Formycon starts <a href=\"https:\/\/www.formycon.com\/en\/press-release\/formycon-starts-antibody-based-drug-development-for-covid-19\/\">antibody-based drug development<\/a> for COVID-19<\/li>\n<li>Formycon informs about current <a href=\"https:\/\/www.formycon.com\/en\/press-release\/formycon-informs-about-the-current-status-of-the-bla-review-process-of-the-lucentis-biosimilar-candidate-fyb201\/\">status of the BLA review process<\/a> of the Lucentis\u00ae Biosimilar-Candidate FYB201<\/li>\n<\/ul>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_tab][vc_tab title=&#8221;2019&#8243; tab_id=&#8221;1612444137033-8-4&#8243; slug=&#8221;2019&#8243;][vc_row_inner][vc_column_inner column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-674378&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; css_animation=&#8221;bottom-t-top&#8221; width=&#8221;1\/1&#8243; column_width_pixel=&#8221;864&#8243;][vc_column_text text_lead=&#8221;yes&#8221;]<\/p>\n<ul>\n<li>Bioeq IP AG exclusively licenses <a href=\"https:\/\/www.formycon.com\/en\/press-release\/bioeq-ip-ag-exclusively-licenses-us-marketing-rights-for-fyb201-to-coherus-biosciences-inc\/\">US Marketing Rights<\/a> for FYB201 to <a href=\"http:\/\/www.coherus.com\">Coherus BioSciences, Inc.<\/a><\/li>\n<li>Formycon announces start of <a href=\"https:\/\/www.formycon.com\/en\/press-release\/formycon-announces-start-of-phase-i-clinical-trial-with-ustekinumab-biosimilar-candidate-fyb202\/\">phase I clinical trial<\/a> with ustekinumab biosimilar candidate FYB202<\/li>\n<li>Formycon places <a href=\"https:\/\/www.formycon.com\/en\/press-release\/formycon-places-cash-capital-increase-of-eur-17-3-million-with-institutional-investor\/\">cash capital increase<\/a> of EUR 17.3 Million with institutional investor<\/li>\n<\/ul>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_tab][vc_tab title=&#8221;2018&#8243; tab_id=&#8221;1534105302-1-471534111567245&#8243; slug=&#8221;2018&#8243;][vc_row_inner][vc_column_inner column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-674378&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; css_animation=&#8221;bottom-t-top&#8221; width=&#8221;1\/1&#8243; column_width_pixel=&#8221;864&#8243;][vc_column_text text_lead=&#8221;yes&#8221;]<\/p>\n<ul>\n<li>Formycon appoints development and production expert <a href=\"https:\/\/www.formycon.com\/en\/press_release\/formycon-appoints-development-and-production-expert-thomas-siklosi-to-the-advisory-board\/\">Thomas Siklosi<\/a> to the Advisory Board<\/li>\n<li>Biosimilar candidate FYB201 shows efficacy comparable to the reference product in <a href=\"https:\/\/www.formycon.com\/en\/press_release\/formycon-and-bioeq-achieve-important-milestone-biosimilar-ranibizumab-candidate-fyb201-shows-efficacy-comparable-to-the-reference-product-in-phase-iii-study\/\">clinical phase III<\/a><\/li>\n<li>Formycon <a href=\"https:\/\/www.formycon.com\/en\/press_release\/formycon-ranks-7th-in-the-financial-times-list-of-europes-1000-strongest-growing-companies\/\">ranks 7th<\/a> in the Financial Times list of Europe\u2019s 1000 strongest-growing companies<\/li>\n<\/ul>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_tab][vc_tab title=&#8221;2017&#8243; tab_id=&#8221;1534105302-2-891534111567245&#8243; slug=&#8221;2017&#8243;][vc_row_inner][vc_column_inner column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-674378&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; css_animation=&#8221;bottom-t-top&#8221; width=&#8221;1\/1&#8243; column_width_pixel=&#8221;800&#8243;][vc_column_text text_lead=&#8221;yes&#8221;]<\/p>\n<ul>\n<li>Formycon and Aristo Pharma establish <a href=\"https:\/\/www.formycon.com\/en\/press_release\/formycon-and-aristo-pharma-are-founding-a-joint-venture-for-the-development-of-fyb202-2\/\">joint venture<\/a> for FYB202<\/li>\n<li>Pipeline news: <a href=\"https:\/\/www.formycon.com\/en\/press_release\/formycon-announces-details-of-further-pipeline-product-fyb202-is-a-biosimilar-candidate-for-stelara-ustekinumab\/\">FYB202<\/a> is a biosimilar candidate for Stelara\u00ae<\/li>\n<li>Formycon changes in new SME stock exchange segment <a href=\"https:\/\/www.formycon.com\/en\/press_release\/formycon-plans-change-in-new-sme-stock-exchange-segment-scale\/\">\u201cScale\u201d<\/a><\/li>\n<\/ul>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_tab][vc_tab title=&#8221;2016&#8243; tab_id=&#8221;1534106178822-2-31534111567245&#8243; slug=&#8221;2016&#8243;][vc_row_inner][vc_column_inner column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-674378&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; css_animation=&#8221;bottom-t-top&#8221; width=&#8221;1\/1&#8243; column_width_pixel=&#8221;800&#8243;][vc_column_text text_lead=&#8221;yes&#8221;]<\/p>\n<ul>\n<li>Focus magazine lists Formycon as growth champion 2017<\/li>\n<li>German Stifterverband awards Formycon for innovative strength<\/li>\n<li>Santo Holding (Deutschland) GmbH tranfers global commercialization rights for FYB201 to Bioeq IP AG<\/li>\n<li>Dr. Carsten Brockmeyer again honored as one of the most influential people in medicines industry<\/li>\n<li>Expansion of product pipeline with fourth biosimilar candidate<\/li>\n<li>Details on FYB203: Formycon develops biosimilar for Eylea\u00ae (aflibercept)<\/li>\n<li>Appointment of biotech expert Professor Johannes Buchner to Advisory Board<\/li>\n<li>Enrollment of first patient in pivotal phase III study with Lucentis\u00ae biosimilar (FYB201)<\/li>\n<\/ul>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_tab][vc_tab title=&#8221;2015&#8243; tab_id=&#8221;1534106216676-3-91534111567245&#8243; slug=&#8221;2015&#8243;][vc_row_inner][vc_column_inner column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-674378&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; css_animation=&#8221;bottom-t-top&#8221; width=&#8221;1\/1&#8243; column_width_pixel=&#8221;800&#8243;][vc_column_text text_lead=&#8221;yes&#8221;]<\/p>\n<ul>\n<li>Formycon and Bioeq initiate pivotal phase III clinical trial with Lucentis\u00ae biosimilar (FYB201)<\/li>\n<li>Out-licensing of second biosimilar to Santo Holding<\/li>\n<li>Medicine Maker: Dr. Carsten Brockmeyer under Top 20 in medicines industry<\/li>\n<li>Capital increase of EUR 11.1 million<\/li>\n<li>Successful GMP inspection<\/li>\n<\/ul>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_tab][vc_tab title=&#8221;2014&#8243; tab_id=&#8221;1534106217483-4-11534111567245&#8243; slug=&#8221;2014&#8243;][vc_row_inner][vc_column_inner column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-674378&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; css_animation=&#8221;bottom-t-top&#8221; width=&#8221;1\/1&#8243; column_width_pixel=&#8221;800&#8243;][vc_column_text text_lead=&#8221;yes&#8221;]<\/p>\n<ul>\n<li>Development of third\u00a0biosimilar begins<\/li>\n<li>Leading East European pharmaceutical manufacturer Polpharma joins FYB201 project as a joint venture partner<\/li>\n<li>Formycon AG appoints top US pharmaceuticals manager Bernhard Hampl to the Advisory Board<\/li>\n<\/ul>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_tab][vc_tab title=&#8221;2013&#8243; tab_id=&#8221;1534106218161-5-01534111567245&#8243; slug=&#8221;2013&#8243;][vc_row_inner][vc_column_inner column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-674378&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; css_animation=&#8221;bottom-t-top&#8221; width=&#8221;1\/1&#8243; column_width_pixel=&#8221;800&#8243;][vc_column_text text_lead=&#8221;yes&#8221;]<\/p>\n<ul>\n<li>Successful completion of capital increase totaling EUR 17.5 million<\/li>\n<li>Start of development of first and second product<\/li>\n<li>Out-licensing of first biosimilar from Formycon product Pipeline to Santo Holding GmbH<\/li>\n<\/ul>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_tab][vc_tab title=&#8221;2012&#8243; tab_id=&#8221;1534106218796-6-71534111567245&#8243; slug=&#8221;2012&#8243;][vc_row_inner][vc_column_inner column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-674378&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; css_animation=&#8221;bottom-t-top&#8221; width=&#8221;1\/1&#8243; column_width_pixel=&#8221;800&#8243;][vc_column_text text_lead=&#8221;yes&#8221;]<\/p>\n<ul>\n<li>Renaming to Formycon AG<\/li>\n<li>Leadership in the development of high-quality biopharmaceutical follow-up-products<\/li>\n<\/ul>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_tab][vc_tab title=&#8221;1999 \u2013 2011&#8243; tab_id=&#8221;1534106465013-12-61534111567245&#8243; slug=&#8221;1999-2011&#8243;][vc_row_inner][vc_column_inner column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-674378&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; css_animation=&#8221;bottom-t-top&#8221; width=&#8221;1\/1&#8243; column_width_pixel=&#8221;800&#8243;][vc_column_text text_lead=&#8221;yes&#8221;]<\/p>\n<ul>\n<li>2011: Scil Technology GmbH licenses its flagship project to Sanofi<\/li>\n<li>2010: Scil Technology GmbH establishes a dedicated research and services unit under the name \u201cFormycon\u201d<\/li>\n<li>2008: Scil Technology GmbH licenses project portfolio to Medtronic<\/li>\n<li>2003: Alongside its own R&amp;D projects, Scil Technology GmbH wins its first service-provider contracts, conducting its first biosimilar development projects on behalf of clients<\/li>\n<li>2001: Analytical laboratory receives GMP certification<\/li>\n<li>1999: Former executives of Boehringer Mannheim found Scil Technology GmbH<\/li>\n<\/ul>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_tab][\/vc_tabs][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; shift_y_fixed=&#8221;yes&#8221; [&hellip;]<\/p>\n","protected":false},"author":23,"featured_media":79673,"parent":78053,"menu_order":3,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-78066","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>History - Formycon AG<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.formycon.com\/en\/company\/history\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"History - Formycon AG\" \/>\n<meta property=\"og:description\" content=\"[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; shift_y_fixed=&#8221;yes&#8221; [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.formycon.com\/en\/company\/history\/\" \/>\n<meta property=\"og:site_name\" content=\"Formycon AG\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-10T08:52:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/08\/geschichte-formycon-keyvisual.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1600\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.formycon.com\/en\/company\/history\/\",\"url\":\"https:\/\/www.formycon.com\/en\/company\/history\/\",\"name\":\"History - Formycon AG\",\"isPartOf\":{\"@id\":\"https:\/\/www.formycon.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.formycon.com\/en\/company\/history\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.formycon.com\/en\/company\/history\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/08\/geschichte-formycon-keyvisual.jpg\",\"datePublished\":\"2018-07-21T13:36:41+00:00\",\"dateModified\":\"2025-01-10T08:52:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.formycon.com\/en\/company\/history\/#breadcrumb\"},\"inLanguage\":\"en\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.formycon.com\/en\/company\/history\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en\",\"@id\":\"https:\/\/www.formycon.com\/en\/company\/history\/#primaryimage\",\"url\":\"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/08\/geschichte-formycon-keyvisual.jpg\",\"contentUrl\":\"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/08\/geschichte-formycon-keyvisual.jpg\",\"width\":1600,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.formycon.com\/en\/company\/history\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.formycon.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Company\",\"item\":\"https:\/\/www.formycon.com\/en\/company\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"History\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.formycon.com\/en\/#website\",\"url\":\"https:\/\/www.formycon.com\/en\/\",\"name\":\"Formycon AG\",\"description\":\"Global Quality Biosimilars\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.formycon.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"History - Formycon AG","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.formycon.com\/en\/company\/history\/","og_locale":"en_US","og_type":"article","og_title":"History - Formycon AG","og_description":"[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; shift_y_fixed=&#8221;yes&#8221; [&hellip;]","og_url":"https:\/\/www.formycon.com\/en\/company\/history\/","og_site_name":"Formycon AG","article_modified_time":"2025-01-10T08:52:33+00:00","og_image":[{"width":1600,"height":800,"url":"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/08\/geschichte-formycon-keyvisual.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.formycon.com\/en\/company\/history\/","url":"https:\/\/www.formycon.com\/en\/company\/history\/","name":"History - Formycon AG","isPartOf":{"@id":"https:\/\/www.formycon.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.formycon.com\/en\/company\/history\/#primaryimage"},"image":{"@id":"https:\/\/www.formycon.com\/en\/company\/history\/#primaryimage"},"thumbnailUrl":"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/08\/geschichte-formycon-keyvisual.jpg","datePublished":"2018-07-21T13:36:41+00:00","dateModified":"2025-01-10T08:52:33+00:00","breadcrumb":{"@id":"https:\/\/www.formycon.com\/en\/company\/history\/#breadcrumb"},"inLanguage":"en","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.formycon.com\/en\/company\/history\/"]}]},{"@type":"ImageObject","inLanguage":"en","@id":"https:\/\/www.formycon.com\/en\/company\/history\/#primaryimage","url":"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/08\/geschichte-formycon-keyvisual.jpg","contentUrl":"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/08\/geschichte-formycon-keyvisual.jpg","width":1600,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/www.formycon.com\/en\/company\/history\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.formycon.com\/en\/"},{"@type":"ListItem","position":2,"name":"Company","item":"https:\/\/www.formycon.com\/en\/company\/"},{"@type":"ListItem","position":3,"name":"History"}]},{"@type":"WebSite","@id":"https:\/\/www.formycon.com\/en\/#website","url":"https:\/\/www.formycon.com\/en\/","name":"Formycon AG","description":"Global Quality Biosimilars","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.formycon.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-11 07:21:06","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"translation_priority","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages\/78066","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/users\/23"}],"replies":[{"embeddable":true,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/comments?post=78066"}],"version-history":[{"count":19,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages\/78066\/revisions"}],"predecessor-version":[{"id":89866,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages\/78066\/revisions\/89866"}],"up":[{"embeddable":true,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages\/78053"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/media\/79673"}],"wp:attachment":[{"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/media?parent=78066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}